CA 72-4

CA 72-4

An immunoassay that detects tumor-associated glycoprotein 72, an antigen found on many mucin-secreting gastrointestinal cancers.
Mentioned in ?
References in periodicals archive ?
Cramer reported that the top-performing marker was CA 125, followed by human epididymis protein 4 (HE4) and CA 72-4.
The objective of this study was to compare ten tumor antigens (carcinoembryonic antigen [CEA], CA 19-9, CA 195, CA 50, CA 72-4, CA 125, CA 15-3, CA 27.29, alpha-fetoprotein [AFP], and Cyfra 21-1) for their diagnostic efficacy in gastric cancer patients.
Keywords: cancer, gastric cancer, stomach cancer, carcinoembryonic antigen, alpha-fetoprotein, CEA, AFP, CA 50, CA 19-9, CA 195, CA 72-4, CA 125, CA 15-3, CA 27.29, Cyfra 21-1, tumor marker.
We have selected a panel of tumour-associated antigens that includes the following markers: carcinoembryonic antigen (CEA), prostate specific antigen (PSA), alpha-fetoprotein (AFP), the carbohydrate antigens CA 19-9, CA 15-3, and CA 72-4, and ferritin.
Measurement of tumour-associated antigens: We divided the serum measurements into two groups, following the methods or assays used: IMX system (Abbott diagnostic division), a commercial microparticle enzymatic immunological assay used for measuring ferritin and PSA; and Enzymum-test (Boehringer Mannheim GmbH diagnostic division), a commercial immunoenzyme assay for CEA, CA 72-4, CA 15-3, AFP, and CA 19-9.
Clinical significance of the tumour markers CA 125 II and CA 72-4 in ovarian carcinoma.
CA 72-4, a human tumor-associated glycoprotein (TAG), is frequently used as a tumor marker for diagnosing and predicting prognosis in gastric and ovarian cancers (1819).
The charts and pathologic findings were reviewed in a blinded fashion, without knowing the preoperative serum YKL-40 and CA 72-4 values.
On the other hand some previous reports made this hypothesis controversial with the higher positivity rate of CEA CA 72-4 and CA 19-9 in the diffuse type of gastric cancer.3852 Our results showed that there was no significant difference between serum tumor marker levels of patients with respect to tumor grade or the presence of ringlet cell type of tumor cells.